Soligenix, Inc. Stock

$3.38

0.60% day before yesterday

Nasdaq, Aug 22, 10:07 pm CET

ISIN

US8342233074

Symbol

SNGX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Soligenix, Inc. Stock price

$3.38

-490.53 99.32% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.02 0.60%

ISIN

US8342233074

Symbol

SNGX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$14.5m

Enterprise Value

$7.2m

Net debt

positive

Cash

$7.3m

Shares outstanding

3.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

4.0

Financial Health

Equity Ratio

45.9%

Return on Equity

-200.7%

ROCE

-293.8%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-10.6m | -

EBIT

$-10.6m | $-12.3m

Net Income

$-9.6m | $-11.2m

Free Cash Flow

$-8.9m

Growth (TTM | estimate)

Revenue

-100.0% | -100.0%

EBITDA

-32.0% | -

EBIT

-32.0% | -30.5%

Net Income

-36.8% | -35.3%

Free Cash Flow

-14.5%

EPS

$-3.1

FCF per Share

$-2.8

Short interest

10.4%

Employees

Rev per Employee

$10.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Soligenix, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Soligenix, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Soligenix, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Soligenix, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.28 4.28	0% 0% -
- Research and Development Expense	6.36 6.36	84% 84% -
EBITDA	-11 -11	32% 32% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-11 -11	32% 32% -
Net Profit	-9.59 -9.59	37% 37% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Soligenix, Inc. Stock News

Neutral

PRNewsWire

●

6 days ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Office of Orphan Products Development of...

Neutral

PRNewsWire

●

10 days ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

PRINCETON, N.J. , Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2025.

Neutral

GlobeNewsWire

●

16 days ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,” featuring Soligenix Inc. (NASDAQ: SNGX).

More Soligenix, Inc. News

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Head office	United States
CEO	Christopher Schaber
Employees	15
Founded	1987
Website	www.soligenix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now